Hagop M. Kantarjian

home / authors / hagop-m-kantarjian

Articles

Kantarjian on Solutions for Oncology Drug Shortages

April 11th 2023

According to Hagop M. Kantarjian, MD, there are options for limited oncology drug shortages that require multi-sector involvement.

Ponatinib and Blinatumomab Demonstrates Durable Responses in PH+ ALL

Hagop M. Kantarjian

September 29th 2022

Hagop M. Kantarjian, MD, discusses what experts should know regarding ponatinib and blinatumomab in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

The Impact of Prominent Treatments in ALL

Hagop M. Kantarjian

July 25th 2022

Hagop M. Kantarjian, MD, discusses the impact of prominent treatments in acute lymphoblastic leukemia.

Evolving Treatment Landscape of Acute Lymphocytic Leukemia

Hagop M. Kantarjian

April 30th 2022

Hagop M. Kantarjian, MD, discusses how the treatment landscape of acute lymphocytic leukemia compares to what it used to be.

Latest Updated Articles

Published: May 6th 2024 | Updated: May 21st 2024

FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors

Published: November 20th 2024 | Updated: November 23rd 2024

Innovative ctDNA Testing Drives Progress in NSCLC Research

Published: November 13th 2024 | Updated: November 23rd 2024

HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC

Published: August 18th 2023 | Updated: November 23rd 2024

Immunotherapy Options for an Older Patient With Metastatic Melanoma

Published: October 19th 2024 | Updated: November 23rd 2024

Expert Takeaway From WCLC Congress Highlights Innovative ADC Showing Promise in SCLC

Published: June 6th 2024 | Updated: November 23rd 2024

Second-Line Targeted Options Considered in ESR1-Mutated Breast Cancer

Do Not Sell My Information

Privacy

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777